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Background
The presence of sarcomatous components (SC) in
gonadal or extragonadal germ cell tumors (GCT) is an
infrequent phenomenon whose clinical outcome and bio-
logical significance remains unsettled. It may cause diag-
nostic pitfalls and treatment failure. In order to define the
clinical and pathological characteristics, prognosis and
biological behavior of these tumors, a clinicopathologic
study of 48 cases of GCT/SC was undertaken, with immu-
nohistochemical studies (IHCS) in 34 of them to define
the phenotype of SC.
Materials and methods
Forty-eight cases of GCT with SC were retrieved from the
files of the Instituto Nacional de Cancerologia, Armed
Forces Institute of Pathology and Mount Sinai Medical
Center (23 gonadal, 23 mediastinal and 2 retroperitoneal
tumors). Routine H&E slides were reviewed and IHCS
were done in 34 cases, with antibodies against actin,
desmin, vimentin, CAM 5.2, S-100 protein, CD34, CD31,
and ulex europeaus lectin. A group of 25 cases of GCT
without sarcomatous component (GCT/NS) were
retrieved for comparison. Survival of both groups was
compared.
Results
Germ cell component was pure teratoma in 27 cases, ter-
atoma mixed with other components in 17, pure semi-
noma in 2, intratubular GCT in 1 and hepatoid yolk sac
tumor in 1. SC was: embryonal rhabdomyosarcoma in 30,
angiosarcoma in 6, leiomyosarcoma in 4, undifferentiated
sarcoma in 4, myxoid liposarcoma in 1, malignant
peripheral nerve sheath tumor in 1, malignant triton
tumor in 1 and epithelioid hemangioendothelioma in 1.
IHCS supported the diagnosis in all cases. Metastases with
combined GCT and SC were observed in 6 cases and
metastases with the SC alone in 5. Metastatic tumor
showed only GCT elements in 3 cases. Follow-up data was
available in 40 cases of the GCT/SC group, 25 patients
(62.5%) died of tumor; 7 (17.5%) were alive with disease
from 1 to 84 months (mean 24 months), and 8 patients
(20%) were alive and free of disease from 5 to 40 months,
in comparison with 7/25 (28%); 1/25 (4%) and 17/25
(68%) respectively in the GCT/NS group (p < 0.001). All
patients were treated by surgery combined with cisplati-
num-based CT plus other agents in selected cases.
Conclusion
Our results suggest that the presence of SC in GCT is a fac-
tor that worsens prognosis, it can behave as an independ-
ent tumor that may metastasize autonomously, and
appears to be resistant to combination CT.
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